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A B S T R A C T
Purpose
Two previous single-arm trials have drawn conﬂicting conclusions regarding the activity of pazopanib
in urothelial cancers after failure of platinum-based chemotherapy.
Patients and Methods
This randomized (1:1) open-label phase II trial compared the efﬁcacy of pazopanib 800mg orally with
paclitaxel (80 mg/m2 days 1, 8, and 15 every 28 days) in the second-line setting. The primary end
point was overall survival (OS).
Results
Between August 2012 and October 2014, 131 patients, out of 140 planned, were randomly
assigned. The study was terminated early on the recommendation of the independent data
monitoring committee because of futility. Final analysis after the preplanned number of deaths
(n = 110) occurred after a median follow-up of 18 months. One hundred ﬁfteen deaths had
occurred at the ﬁnal data extract presented here. Median OS was 8.0 months for paclitaxel (80%
CI, 6.9 to 9.7 months) and 4.7 months for pazopanib (80% CI, 4.2 to 6.4 months). The hazard ratio
(HR) adjusted for baseline stratiﬁcation factors was 1.28 (80% CI, 0.99 to 1.67; one-sided P = .89).
Median progression-free survival was 4.1 months for paclitaxel (80% CI, 3.0 to 5.6 months)
and 3.1 months for pazopanib (80% CI, 2.7 to 4.6 months; HR, 1.09; 80% CI, 0.85 to 1.40; one-
sided P = .67). Discontinuations for toxicity occurred in 7.8% and 23.1% for paclitaxel and
pazopanib, respectively.
Conclusion
Pazopanib did not have greater efﬁcacy than paclitaxel in the second-line treatment of urothelial
cancers. There was a trend toward superior OS for paclitaxel.
J Clin Oncol 35:1770-1777. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Patients with advanced/metastatic urothelial cancer
(UC) are initially treated with platinum-based
chemotherapy.1,2 This results in responses and
subsequent clinical beneﬁt. However, the vast ma-
jority of these patients relapse and die as a result of
their disease. When relapse occurs after initial che-
motherapy, further chemotherapy, such as pacli-
taxel, docetaxel, or vinﬂunine, is recommended.3,4
Vinﬂunine is licensed in Europe in this setting.
However, other agents are more widely used
globally.3,5,6 At the time this study started, no
chemotherapy agents were approved in this set-
ting in the United States.
Outcomes for these patients are particularly
poor, with a median survival in the region of
8 months.3 To date, no regimen has a proven
survival advantage over best supportive care in
randomized trials.6 Results from randomized
trials with immune therapies in this setting are
awaited.
There is in vitro and clinical rationale for
targeting vascular endothelial growth factor (VEGF)
in UC.7,8 Pazopanib is a VEGF receptor tyrosine
kinase inhibitor with a favorable toxicity proﬁle.9 It
is licensed in a number of malignancies, including
renal cancer.9 Preliminary data from two single-arm
phase II studies in platinum-refractory metastatic
UC are contradictory.10,11 Clinical beneﬁt was as
high as 80% in one study, whereas the other showed
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limited activity with no responses. To clarify this issue and plan for
a randomized phase III study, the United Kingdom Bladder Cancer
Clinical Studies Group tested pazopanib against weekly paclitaxel in
a randomized phase II study. The control armwas chosen on the basis
of previously published phase II data and a survey, before the study,
which showed that paclitaxel was the most widely used drug in this
setting in the UK.3,12
PATIENTS AND METHODS
Patients
Patients participating in this study were required to have: histolog-
ically conﬁrmed transitional-cell carcinoma of the bladder, renal pelvis,
ureter, or urethra that was locally advanced or metastatic (T4b and/or N1-3
and/or M1); progressive disease during or after one prior platinum-based
chemotherapy regimen for advanced disease (patients may have had two
platinum-containing regimens if one of these was administered as
adjuvant/neoadjuvant treatment), with progression of disease determined
radiologically by sites; measurable disease by Response Evaluation Criteria
in Solid Tumors (RECIST) 1.1; adequate organ function (bone marrow,
liver, and renal function); signed and dated informed consent; and an
Eastern Cooperative Oncology Group performance status of 0 or 1. Pa-
tients with established cardiac or GI disease, uncontrolled hypertension,
a recent history of bleeding, thrombotic events, or major surgery (within
6 weeks) were excluded from the study. Patients with untreated brain
metastasis, signiﬁcant prior malignancy, or prior exposure to taxane
chemotherapy or VEGF-targeted therapy were also excluded.
Outcome Measures
Overall survival (OS) from date of randomization was the primary
outcomemeasure. Secondary outcomemeasures included toxicity according
to Common Terminology Criteria for Adverse Events v4.02, response rate
(RR) by RECIST 1.1, progression-free survival (PFS), and clinical beneﬁt rate
(CBR; proportion of patients with complete response, partial response, or
stable disease) 12 and 24 weeks after start of treatment.
Quality of life was assessed using the validated bladder cancer–
speciﬁc tool, Functional Assessment of Cancer Therapy–Bladder (FACT-
Bl), which assesses physical, social/family, emotional, and functional
well-being and additional concerns domains to give an overall score. It also
combines the physical, functional, and cancer-speciﬁc subscales (those
most likely to change in a chemotherapy clinical trial) to give a trial
outcome index.
Randomization, Treatment, and Follow-Up
This was a two-arm, open-label randomized (1:1) phase II study (see
supplementary data). A computerized algorithm, which used a minimi-
zation approach13 and incorporated a random component to avoid pre-
dictability, was used to randomly assign patients and ensure that the groups
were well matched with respect to the following factors: response to
previous treatment (time to progression: # 6 months v . 6 months),
presence of visceral and/or bone metastasis, performance status, and in-
vestigational site. Patients in the control arm received paclitaxel 80 mg/m2
by intravenous infusion on days 1, 8, and 15 of a 28-day cycle, with
a maximum duration of 24 weeks. Dose reductions (to 70 then 60 mg/m2)
and interruptions were permitted to manage toxicity. Patients in the in-
vestigational arm received pazopanib 800 mg orally once daily until
progression. Dose reductions according to the manufacturer’s instruction
and interruptions (up to 14 days) were permitted to manage toxicity.
Patients were assessed every four weeks for the ﬁrst 24 weeks and then six-
weekly. Cross-section imaging to assess RR and PFS were performed
12-weekly until progression.
Statistical Consideration and Oversight
The study was designed to detect a 50% improvement in median
overall survival among patients receiving pazopanib compared with
paclitaxel (improvement from 8 months to 12 months with 90%
power, 20% one-sided level of statistical signiﬁcance, or equivalently
with 80% power at the 10% level of statistical signiﬁcance). This
required 110 events, which could be achieved with 140 patients (70 per
arm). The study design was based around a phase II screening design,
with the three-outcome design forming the basis of the decision-
making process.14,15 A result favoring pazopanib that was signiﬁcant at
the one-sided 10% level would suggest that a subsequent phase III trial
should be performed. A result in favor of pazopanib that was sta-
tistically signiﬁcant at the one-sided 20% level, but not at the one-
sided 10% level, would require other supportive data in terms of
a statistically signiﬁcant improvement in PFS, at the 10% level, to
indicate a phase III study was warranted. A result not reaching sta-
tistical signiﬁcance at the 20% level would suggest that no further
investigation of pazopanib should be performed in this setting.
The primary analysis of the overall survival end point was con-
ducted on an intention-to- treat basis. OS and PFS were compared
between the study arms in the context of the hazard ratio (HR) from
a Cox model incorporating study arm and the factors used in the
minimization algorithm. A test for interaction was conducted to assess
whether any observed effect of the study intervention depended on the
other clinical factors used in the minimization algorithm. The ﬁnal
analysis was planned at the end of the minimum follow-up period once
the required number of events (110 deaths) had been observed. A
Kaplan-Meier curve was used to illustrate the relative OS in the two
treatment arms. Toxicity was compared between the study arms using
a Mann-Whitney test. Clinical beneﬁt rate was compared using the odds
ratio (OR) from a logistic regression model incorporating study arm and
the factors used in the minimization algorithm. Quality-of-life data were
calculated and interpreted using FACT-Bl scoring and interpretation
materials (http://www.facit.org/FACITOrg/Questionnaires) and assessed
using area under the curve (AUC) techniques.16 Missing values were
ﬁlled in using interpolation or last value carried forward, as appropriate.
Missing baseline values were imputed with the earliest available value.
The calculated AUC scores were standardized by the quality-of-life as-
sessment duration, which was time to progression, death, or 97 weeks,
whichever was shortest. These standardized AUC scores were adjusted by
subtracting the cycle one/week one value. To adjust for multiple testing,
the false discovery rate (FDR) was calculated using the p.adjust function
(fdr option) of the stats library in R.17
The trial was open labeled, and an independent data monitoring
committee monitored the adverse events (for toxicity) and efﬁcacy (for
futility). A trial steering committee convened on a regular basis. The trial
had appropriate ethical and regulatory approval (ISRCTN73030316).
RESULTS
Between August 2012 and October 2014, 131 patients were ran-
domly assigned from 24 United Kingdom sites, 65 to receive
paclitaxel and 66 to receive pazopanib. Recruitment was termi-
nated prematurely (October 14, 2014) on recommendation of the
independent data monitoring committee after an interim analysis
of the ﬁrst 60 deaths in the study showed that the trial was unlikely
to achieve the objective of demonstrating superiority for pazopanib
compared with paclitaxel. At this time, 131 of 140 planned patients
had been enrolled.
Investigators were informed of this decision immediately, but
patients were permitted to continue with their allocated study
treatment if both the patient and the investigator believed it was in
the patient’s best interests. Patient distribution in the trial is
jco.org © 2017 by American Society of Clinical Oncology 1771
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illustrated in Figure 1 (CONSORT diagram). No patients stopped
pazopanib because of futility of the trial. At the time of ﬁnal data
extraction (May 20, 2016), there were 115 OS events. The median
follow-up of the patients was 18 months.
Patient Characteristics
Patient characteristics are listed in Table 1. Notably, only two
patients had prior cystectomy; 24.4% had liver metastases, and
61% had impaired performance status.
Efficacy
Median OS from randomization was 8.0 months (80% CI,
6.9 to 9.7 months) and 4.7 months (80% CI, 4.2 to 6.4 months)
for paclitaxel and pazopanib, respectively (adjusted HR, 1.28;
80% CI, 0.99 to 1.67; one-sided P = .89; two-sided P = .23).
Median PFS was 4.1 months (80% CI, 3.0 to 5.6 months) and
3.1 months (80% CI, 2.7 to 4.6 months) for paclitaxel and
pazopanib, respectively (adjusted HR, 1.09; 80% CI, 0.85 to
1.40; one-sided P = .67; two-sided P = .66). Kaplan-Meier
survival distributions are show in Figure 2 (Kaplan-Meier
Assessed for eligibility
(N = 304)
Patients randomly assigned
(n = 131)
Excluded
  Not meeting inclusion criteria
  Refused to participate
  Other reasons
  Reason unknown
(n = 173)
(n = 87)
(n = 34)
(n = 29)
(n = 23)
Arm A – Paclitaxel 80 mg/m2
Allocated to intervention
  Received allocated intervention
  Received allocated intervention
    but strictly ineligible
  Did not receive allocated
    intervention
(n = 65)
(n = 61)
(n = 3)
(n = 1)
Allocated to intervention
  Received allocated intervention
  Received allocated intervention
    but strictly ineligible
  Did not receive allocated
    intervention
(n = 66)
(n = 62)
(n = 3)
(n = 1)
Arm B – Pazopanib 800 mg
Safety population
Eligible population
ITT population
Analyzed
Safety population
Eligible population
ITT population
Analyzed
(n = 65)
(n = 62)
(n = 64)
(n = 66)
(n = 63)
(n = 65)
Fig 1. CONSORT diagram. ITT, intent to treat.
Table 1. Distribution of Patient Characteristics
Characteristic Paclitaxel (n = 65) Pazopanib (n = 66)
Male 75 67
Age, years 70 (63-77) 69 (61-75)
Ethnicity
White 91 95
Asian 3 2
Afro-Caribbean 2 2
Other 4 1
ECOG performance status
0 39 39
1 52 53
2 9 8
Bladder primary 66 71
T4 disease at diagnosis 20 15
Liver metastases 29 20
Nodal metastases 45 53
Time since last platinum therapy to randomization, days 146 (65-244) 161 (81-273)
# 6 months from previous treatment to progression 75 73
Time from initial diagnosis to randomization, days 444 (325-661) 478 (300-781)
NOTE. Data presented as percentage or median (interquartile range).
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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curves for OS and PFS). OS and PFS by preplanned subgroups
are illustrated in Figure 3. Nine (13.9%) of 65 and three (4.5%)
of 66 patients had complete or partial response at 12 weeks in
the paclitaxel and pazopanib arms, respectively. The CBR
(proportion of patients with complete response, partial re-
sponse, or stable disease) at 12 weeks was 40% for the pac-
litaxel arm and 36.4% for pazopanib (adjusted OR, 1.27; 80%
CI, 0.78 to 2.06; one-sided P = .73; two-sided P = .54). At
24 weeks, the CBR was 18.5% and 12.1% respectively (adjusted
OR, 1.76; 80% CI, 0.92 to 3.39; one-sided P = .87; two-sided
P = .27).
Treatment Exposure and Discontinuation
Overall, 22 patients (34.4%) in the control arm received
the planned six cycles of paclitaxel; the median number of
cycles was four. The median time on pazopanib was 10.9 weeks
(80% CI, 9.9 to 11.9 weeks). Five patients (7.8%) and 15
patients (23.1%) discontinued treatment because of toxicity,
and 28 patients (43.8%) and 40 patients (61.5%) discontinued
because of disease progression for paclitaxel and pazopanib,
respectively. Sixteen patients (25%) and 21 patients (32.3%)
required one or more dose reductions for paclitaxel and
pazopanib, respectively.
Treatment-Emergent Adverse Events
Thirty-nine percent and 51% of patients experienced one
or more high-grade (3 or 4) treatment-emergent adverse events
(AEs) during the study treatment period; 27% and 38% ex-
perienced one or more high-grade AEs that were attributed to
the study drug (for paclitaxel and pazopanib, respectively). The
most common treatment-emergent AEs are summarized in
Table 2. Toxicity was in line with expected AE proﬁles, with
neuropathy and neutropenia more prominent with paclitaxel
and hypertension, diarrhea, and transaminitis more prominent
with pazopanib. The most common AEs resulting in discon-
tinuation of pazopanib were fatigue, nausea, and vomiting.
Quality of Life
Seventeen patients were excluded from the FACT-Bl AUC
analyses, because of a lack of data (usually incomplete or absence
of completed questionnaires [76%]). FACT-Bl trial outcome
index is signiﬁcantly reduced in the pazopanib arm (baseline
adjusted standardized AUC median, 22.7; interquartile range
(IQR),210.3 to 0.0) compared with paclitaxel (baseline adjusted
standardized AUC median, 0.0; IQR, 24.9 to 2.0); two-sided
P = .0028 (FDR adjusted P = .0034). Similarly, FACT-Bl total
score is also signiﬁcantly reduced with pazopanib (baseline
adjusted standardized AUC median, 23.8; IQR, 29.8 to 0.0)
compared with paclitaxel (baseline adjusted standardized AUC
median, 0.0; IQR, 25.2 to 0.8); two-sided P = .0034 (FDR
adjusted P = .0034). The change from baseline in each quality of
life measure is illustrated in Figure 4.
Subsequent Therapies
Twenty percent and 24% of patients received further
chemotherapy, 15% and 18% received palliative radiotherapy,
and 6% and 0% received an immune checkpoint inhibitor after
completing study treatment in the paclitaxel and pazopanib
arms, respectively. Of the four patients receiving immune
checkpoint inhibitors, one received nivolumab and three re-
ceived atezolizumab.
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Fig 2. Kaplan-Meier survival distribution for (A) overall survival, and (B) progression-free survival used on the intent-to-treat (ITT) population using the Kaplan-Meier
methodology. Hazard ratios (HRs) were calculated using the Cox model and factors in the minimization algorithm.
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DISCUSSION
There is no globally accepted standard of care in second-line
treatment of advanced UC after the failure of prior platinum-
based chemotherapy.1 A variety of chemotherapy drugs have
demonstrated modest activity in small proportions of pa-
tients, but none have demonstrated conclusive clinical beneﬁts
compared with best supportive care.3 It is possible that such
beneﬁts exist among a deﬁned subgroup of patients, but there
are no data to guide us in making such a selection. Vinﬂunine is
licensed in Europe despite no survival beneﬁt over best sup-
portive care in the intention-to-treat population.6 The OS of
these patients was 6.9 months, with a nonsigniﬁcant 22% re-
duction in the risk of death over best supportive care. Other
agents, such as single-agent taxanes or chemotherapy dou-
blets, have been investigated in single-arm trials without
success. Meta-analysis suggests doublets are not superior to
single-agent therapy.18 Median OS for patients in these
Favors pazopanib Favors paclitaxel
Overall (n = 131)
> 6 months (n = 34)
≤ 6 months (n = 97)
Progression after previous treatment (P = .81)
2 (n = 11)
1 (n = 69)
0 (n = 51)
ECOG at randomization (P = .3)
No (n = 34)
Yes (n = 97)
Visceral metastatic disease (P = .52)
HR
HR = 1 Overall HR for study
10.05.01.00.50.1
Favors pazopanib Favors paclitaxel
Overall (n = 131)
> 6 months (n = 34)
≤ 6 months (n = 97)
Progression after previous treatment (P = .51)
2 (n = 11)
1 (n = 69)
0 (n = 51)
ECOG at randomization (P = .03)
No (n = 34)
Yes (n = 97)
Visceral metastatic disease (P = .94)
HR
HR = 1 Overall HR for study
10.05.01.00.50.1
B
A
Fig 3. Forest plot of (A) overall survival, and
(B) progression-free survival by subgroup. Hazard
ratios (HRs) were calculated using Cox model
incorporating study arm and the factors used
in the minimization algorithm. ECOG, Eastern
Cooperative Oncology Group.
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chemotherapy trials remains well below 10 months and is
usually closer to 7 months.3
Recent early-phase single-arm trials of immune checkpoint
inhibitors have clearly demonstrated efﬁcacy for these drugs in
a signiﬁcant proportion of patients.19 Atezolizumab is an inhibitor
of programmed death-ligand 1. Results from a large phase II study
in a chemotherapy-refractory UC population showed signiﬁcant
activity, particularly in tumors that overexpress the programmed
death-ligand 1 biomarker in the immune component of the tumor
(RR, 27%; 95% CI, 19% to 37%).20 Overall survival for the entire
cohort was 7.9 months (6.7, NE). Atezolizumab is licensed in both
biomarker-positive and -negative patients in the United States in
this setting. A recent randomized phase III trial showed that
pembrolizumab, an inhibitor of programmed death-1, prolonged
survival compared with chemotherapy agents, including taxanes,
in platinum-refractory UC (HR, 0.73; 95% CI, 0.59 to 0.91;
P = .002).21
The results presented here show pazopanib is not better than
weekly paclitaxel. Indeed, the trial was stopped with nine patients
still to recruit after a futility analysis indicated that the trial would
not meet its primary objective of demonstrating superiority of
pazopanib over paclitaxel. Final results showed a trend toward an
OS beneﬁt for paclitaxel, with an HR of 1.28 (80% CI, 0.99 to 1.67;
one-sided P = .89; two-sided P = .23) in favor of paclitaxel. Other
efﬁcacy results for paclitaxel were in line with previous results for
chemotherapy in the second-line setting (RR, 14%; and median
PFS, 4.1 months), and the fractionated chemotherapy schedule
used here was generally well tolerated. The reasons for the relative
lack of efﬁcacy for pazopanib remain unclear. Previous data with
pazopanib in this setting were contradictory, highlighting short-
comings of single-arm single-institution trials in UC, where patient
baseline characteristics have a signiﬁcant effect on outcome. The
data presented here support the study by Pili et al11 suggesting
limited activity. Pazopanib was administered at standard doses and
was relatively well tolerated. However, 23% of patients stopped
therapy because of toxicity, compared with 8% of those on
chemotherapy. Thus, lack of exposure to study drug may have
partly contributed to the relatively poor outcomes for those re-
ceiving pazopanib. Pharmacokinetic studies were not performed in
this study, but there is no reason to suggest the lack of efﬁcacy was
dose related (32% of patients required a dose reduction, which is in
line with those seen with pazopanib in other settings).
VEGF-targeted therapy has been investigated previously
in UC with mixed results. Single-arm trials are difﬁcult to
interpret, as described above. Three randomized trials are
noteworthy. The ﬁrst is a phase II trial with ramucirumab (an
anti-VEGF receptor 2 antibody), which, when administered in
combination with taxane-based chemotherapy, signiﬁcantly
delayed PFS compared with taxane and placebo.22 Although
these positive results may be drug speciﬁc, it is also possible
that combination strategies (chemotherapy/VEGF-targeted
therapy) are preferable to the single-agent strategy used in
our study, although other such combinations have proven
difﬁcult to deliver.23
The second study of note relates to maintenance sunitinib
administered after ﬁrst-line chemotherapy, compared with pla-
cebo. This trial was stopped early, and the numbers were small.
However, median PFS was 2.9 versus 2.7 months for sunitinib and
placebo, respectively. Also, patients whose disease progressed on
placebo crossed over to receive sunitinib (n = 16). These patients
did not beneﬁt from therapy, with only one response, suggesting
limited activity for single-agent VEGF therapy in line with those
seen in our study.24 The third study investigated paclitaxel with or
without vandetanib, which is a broad-spectrum tyrosine kinase
inhibitor (TKI) with VEGF receptor inhibition. This study showed
no improvement in outcome associated with the addition of the
targeted therapy. Together, these studies fail to form a consensus on
the role of VEGF-targeted therapy in UC.25
It is possible that there are molecularly deﬁned subgroups of
patients who do beneﬁt from VEGF-targeted therapy, or, con-
versely, who may be speciﬁcally sensitive to taxanes. As part of this
trial, we have a comprehensive archival tissue and blood collection.
Table 2. Treatment-Emergent Adverse Events
Toxicity
Paclitaxel (n = 64) Pazopanib (n = 65)
P*Any Grade ($ 1) Grade $ 3 Any Grade ($ 1) Grade $ 3
Any adverse event 94 27 91 39 —
Neutropenia 36 6 9 0 .001
Thrombocytopenia 2 0 9 2 .32
Hypophosphatemia 38 6 18 0 .010
Elevated alanine transaminase 34 2 48 9 .056
Hypertension 0 0 20 9 , .001
Alopecia 41 0 2 0 , .001
Nausea 41 0 42 3 .49
Anorexia 16 0 31 0 .026
Diarrhea 27 2 49 6 .007
Altered taste 5 0 14 0 .003
Fatigue 72 5 74 9 .56
Mucositis 20 2 15 0 .50
Neuropathy 38 2 3 0 , .001
PPE 0 0 11 2 .13
NOTE. Data presented as percentage. All percentages presented are based on the safety population (n = 129). Adverse events measured by Common Terminology
Criteria for Adverse Events v4.02. The most common 14 events are given, which occurred in . 9% of patients.
*Two-sided P values from Mann-Whitney test (on the basis of ordered toxicity grades).
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Analyses are ongoing to establish putative predictive markers to
differentiate those patients who may beneﬁt from one or other of
these approaches.
High levels of grade 3 or 4 toxicity occurred in both arms. This
was numerically higher in the pazopanib arm. Speciﬁc toxicity was
in line with expected toxicity associated with the respective drugs.
Higher levels of discontinuation of study drug occurred with
pazopanib (23% v 8%). Quality of life dropped from baseline in
both arms, although more markedly with pazopanib. Overall, these
results demonstrate the difﬁculty of giving systemic therapy in
these patients and do not suggest pazopanib is easily tolerable in
this setting.
No patients switched from pazopanib to paclitaxel when the
study was stopped, despite the opportunity being offered to them.
We speculate that this is a reﬂection of the perceived inactivity of
chemotherapy in this setting.
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Fig 4. Quality of life analysis of change
from baseline in (A) Functional Assessment
of Cancer Therapy–Bladder (FACT-Bl) total
score, and (B) FACT-Bl trial outcome index
(TOI) by arm, assessed using area under the
curve techniques.15 Number of data points
is included. EoT, end of treatment.
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The study presented here conclusively showed that single-
agent pazopanib should not be further pursued in unselected
patients, resolving the previous controversy in this setting. Al-
ternative approaches should not be excluded with this or other
VEGF-targeted therapy. Also, a biomarker-based personalized
approach should not be discounted, although VEGF-based bio-
markers have been elusive.
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